

**UBRELVY**<sup>®</sup>  
(ubrogepant) tablets | 50mg, 100mg

**QULIPTA**<sup>®</sup>  
(atogepant) tablets

The only oral CGRP treatment proven to prevent both **EPISODIC** AND **CHRONIC** MIGRAINE<sup>1</sup>

# RETHINKING MIGRAINE

CGRP = calcitonin gene-related peptide  
Reference: 1. QULIPTA (atogepant). Package insert. AbbVie Inc; 2023.

**A MIGRAINE PORTFOLIO PRESENTATION INCLUDING PRODROME  
CLINICAL EVIDENCE FOR UBRELVY<sup>®</sup>**

**MAX  
EDGE**  
P R O G R A M  
Education Growth Expertise

**Saturday, October 26, 2024  
at 7:00 AM ET**

**Hyatt Regency and Greater Columbus Convention  
Center in downtown Columbus**  
350 North High Street, Columbus, OH

**PRESENTED BY:**



**Susan Whitt, PA**  
Internal Medicine  
The Facebar  
Canal Winchester OH



**Please RSVP using the link or QR code at left:**  
<http://www.medforcereg.com/SALG207413>  
For questions, contact your AbbVie Representative  
Preston Hawk Phone: 4402218459 Email:  
preston.hawk@abbvie.com

## INDICATION

UBRELVY<sup>®</sup> (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

## IMPORTANT SAFETY INFORMATION

### CONTRAINDICATIONS

**Drug Interactions:** UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

**Hypersensitivity Reactions:** UBRELVY is contraindicated in patients with a history of serious hypersensitivity to ubrogepant or any ingredient of the product. Cases, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions were not serious, and some led to discontinuation. If a serious or severe reaction occurs, discontinue UBRELVY and institute appropriate therapy.

### ADVERSE REACTIONS

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

**Please see accompanying full Prescribing Information or visit**  
[https://www.rxabbvie.com/pdf/ubrelvy\\_pi.pdf](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf).

The Phase 3 studies for UBRELVY and QULIPTA that supported product approval had no patients on concomitant medication that acted on the CGRP pathway.

## INDICATION

QULIPTA<sup>®</sup> (atogepant) is indicated for the preventive treatment of migraine in adults.

## IMPORTANT SAFETY INFORMATION

### CONTRAINDICATIONS

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

### WARNINGS AND PRECAUTIONS

Cases, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, have been reported with use of QULIPTA. Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction occurs, discontinue QULIPTA and institute appropriate therapy.

### ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.

**Dosage form and strengths:** QULIPTA is available in 10 mg, 30 mg, and 60 mg tablets.

**Please see accompanying full Prescribing Information or visit**  
[https://www.rxabbvie.com/pdf/qulipta\\_pi.pdf](https://www.rxabbvie.com/pdf/qulipta_pi.pdf).

*This promotional event is brought to you by AbbVie and is not certified for continuing medical education.*

*The speaker is a paid consultant presenting on behalf of AbbVie and the information being presented is consistent with FDA guidelines. This event is conducted in accordance with the PhRMA Code on Interactions with Healthcare Professionals and is limited to invited healthcare professionals (HCPs). Attendance by guests or spouses is not appropriate. It is AbbVie's policy to include only those healthcare professionals involved in patient care consistent with our product indication(s).*

*The cost of meals and refreshments provided to U.S. HCPs may be subject to public disclosure. AbbVie's disclosure will allocate the cost of meals and refreshments equally across all attendees regardless of actual consumption. AbbVie abides by applicable federal and state laws, which prohibit or limit the ability of government employees and certain healthcare professionals to accept items of value from AbbVie. Please comply with applicable law.*